PT752248E
(pt)
*
|
1992-11-13 |
2001-01-31 |
Idec Pharma Corp |
Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
|
US7744877B2
(en)
*
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
BR9913645A
(pt)
|
1998-08-11 |
2001-09-25 |
Idec Pharma Corp |
Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
TWI253934B
(en)
*
|
1998-11-09 |
2006-05-01 |
Idec Pharma Corp |
Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant
|
AU761844C
(en)
|
1998-11-09 |
2004-09-23 |
F. Hoffmann-La Roche Ag |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
KR100944575B1
(ko)
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
EP1626993B1
(en)
*
|
2003-05-09 |
2015-03-11 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
AR044388A1
(es)
*
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
WO2005023302A2
(en)
*
|
2003-08-29 |
2005-03-17 |
Genentech, Inc. |
Anti-cd20 therapy of ocular disorders
|
PL1692182T3
(pl)
|
2003-11-05 |
2010-09-30 |
Roche Glycart Ag |
Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
|
FR2867982B1
(fr)
*
|
2004-03-26 |
2007-07-20 |
Jean Marie Andrieu |
Procede pour amplifier l'activite de vaccins therapeutiques
|
BRPI0509419A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
|
WO2005115453A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Genentech, Inc. |
Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
|
EP1735000A2
(en)
*
|
2004-04-16 |
2006-12-27 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
ZA200608982B
(en)
*
|
2004-05-05 |
2008-06-25 |
Genentech Inc |
Preventing autoimmune disease by using an anti-CD20 antibody
|
DE102004024617A1
(de)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
NZ604082A
(en)
*
|
2004-06-04 |
2014-09-26 |
Genentech Inc |
Method for treating multiple sclerosis
|
WO2006002474A1
(en)
*
|
2004-07-02 |
2006-01-12 |
The Walter And Eliza Hall Institute Of Medical Research |
Alpha-helical mimetics
|
WO2006085967A2
(en)
*
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
ES2426817T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
EP1812060A2
(en)
*
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
FR2879204B1
(fr)
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
US10206998B2
(en)
|
2005-01-12 |
2019-02-19 |
Proteonova, Inc. |
Modular targeted therapeutic agents and methods of making same
|
WO2006076417A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Proteonova, Inc. |
Method for making targeted therapeutic agents
|
RS59399B1
(sr)
|
2005-03-23 |
2019-11-29 |
Genmab As |
Antitela protiv cd38 za lečenje multiplog mijeloma
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質viモノクローナル抗体
|
EP1915394B1
(en)
|
2005-05-20 |
2021-01-27 |
Lonza Biologics plc. |
High-level expression of recombinant antibody in a mammalian host cell
|
FR2886298A1
(fr)
*
|
2005-05-24 |
2006-12-01 |
Ifremer |
Anticorps ou fragment d'anticorps couple a un agent immunogene
|
KR20080031001A
(ko)
*
|
2005-06-02 |
2008-04-07 |
아스트라제네카 아베 |
Cd20에 대한 항체 및 그의 용도
|
ES2530265T3
(es)
|
2005-07-21 |
2015-02-27 |
Genmab A/S |
Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
|
SI2298815T1
(sl)
|
2005-07-25 |
2015-08-31 |
Emergent Product Development Seattle, Llc |
Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
JP6088723B2
(ja)
|
2005-11-23 |
2017-03-01 |
ジェネンテック, インコーポレイテッド |
B細胞アッセイに関する組成物及び方法。
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
KR20080110800A
(ko)
|
2006-03-15 |
2008-12-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
TWI390034B
(zh)
|
2006-04-06 |
2013-03-21 |
Kyowa Hakko Kirin Co Ltd |
Novel anti-CD98 antibody
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
EP2046383B1
(en)
|
2006-07-04 |
2014-11-19 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
LT2081595T
(lt)
*
|
2006-09-26 |
2019-07-10 |
Genmab A/S |
Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
|
SI2066351T1
(sl)
*
|
2006-10-02 |
2016-02-29 |
E.R. Squibb & Sons, L.L.C. |
Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
WO2008091740A2
(en)
|
2007-01-22 |
2008-07-31 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
EP1970384A1
(en)
|
2007-03-14 |
2008-09-17 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
PE20090190A1
(es)
*
|
2007-03-23 |
2009-03-22 |
Smithkline Beecham Corp |
Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
|
US9212230B2
(en)
|
2007-03-29 |
2015-12-15 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
EP2468302A1
(en)
|
2007-05-29 |
2012-06-27 |
Novartis AG |
New indications for anti-IL-1beta therapy
|
EP1997832A1
(en)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
AU2008255352B2
(en)
|
2007-05-31 |
2014-05-22 |
Genmab A/S |
Stable IgG4 antibodies
|
CA2689695A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
MY147651A
(en)
*
|
2007-07-31 |
2012-12-31 |
Regeneron Pharma |
Human antibodies to human cd20 and method of using thereof
|
AU2008295140A1
(en)
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type I and type II anti-CD20 antibodies
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
ES2565202T3
(es)
|
2007-10-16 |
2016-04-01 |
Zymogenetics, Inc. |
Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
|
EP2205277B1
(en)
*
|
2007-10-22 |
2017-07-26 |
Genmab A/S |
Novel antibody therapies
|
PL2565206T3
(pl)
|
2007-10-30 |
2017-08-31 |
Genentech, Inc. |
Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
|
JP2011507897A
(ja)
*
|
2007-12-21 |
2011-03-10 |
ジェネンテック, インコーポレイテッド |
リツキシマブ抵抗性関節リウマチ患者の治療
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
DK2268310T3
(en)
*
|
2008-03-25 |
2016-08-15 |
Roche Glycart Ag |
APPLICATION OF A TYPE II ANTI-CD20 ANTIBODY WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTIN AND DOXORUBICINE TO TREAT NON-HODGINE
|
WO2009126944A1
(en)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US20090269339A1
(en)
*
|
2008-04-29 |
2009-10-29 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
ES2527943T5
(es)
|
2008-08-14 |
2019-03-07 |
Genentech Inc |
Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas
|
US20100068210A1
(en)
|
2008-09-10 |
2010-03-18 |
Ji Junyan A |
Compositions and methods for the prevention of oxidative degradation of proteins
|
EP2166021A1
(en)
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
CA3053156A1
(en)
|
2008-12-03 |
2010-06-10 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP5828151B6
(ja)
*
|
2009-01-06 |
2018-09-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
アテローム性動脈硬化の処置のためのb細胞枯渇剤
|
AU2010204666A1
(en)
*
|
2009-01-16 |
2011-07-21 |
Glaxosmithkline Llc |
Treatment of a cancer using a combination of bendamustine and an anti-CD20 antibody
|
CN107028969A
(zh)
|
2009-02-20 |
2017-08-11 |
加尼梅德药物公司 |
用于癌症诊断和治疗的方法和组合物
|
US20100247484A1
(en)
*
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
JP5589077B2
(ja)
|
2009-07-20 |
2014-09-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
SG178322A1
(en)
|
2009-08-14 |
2012-03-29 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
|
CA2772929A1
(en)
|
2009-09-03 |
2011-03-11 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
US20110070227A1
(en)
*
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
EP2496604B1
(en)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Canine anti-cd20 antibodies
|
LT2499161T
(lt)
|
2009-11-11 |
2017-11-27 |
Ganymed Pharmaceuticals Gmbh |
Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
|
EP2322555A1
(en)
|
2009-11-11 |
2011-05-18 |
Ganymed Pharmaceuticals AG |
Antibodies specific for claudin 6 (CLDN6)
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
TW201129383A
(en)
*
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
JP5841072B2
(ja)
*
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
Cd20抗体およびその使用
|
MX354867B
(es)
|
2010-03-22 |
2018-03-23 |
Genentech Inc Star |
Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
EA201201435A1
(ru)
|
2010-04-20 |
2013-04-30 |
Генмаб А/С |
ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
MX346731B
(es)
†
|
2010-04-23 |
2017-03-30 |
Genentech Inc * |
Producción de proteínas heteromultiméricas.
|
CA2795544A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
WO2011139718A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
EP3613774A1
(en)
|
2010-06-09 |
2020-02-26 |
Genmab A/S |
Antibodies against human cd38
|
AU2011270828B2
(en)
|
2010-06-24 |
2015-09-24 |
Genentech, Inc. |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
EP2404936A1
(en)
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
MX2013001302A
(es)
|
2010-08-03 |
2013-03-08 |
Hoffmann La Roche |
Biomarcadores de leucemia linfocitica (cll).
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
CA2813466A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
|
BR112013011305A2
(pt)
|
2010-11-08 |
2017-07-25 |
Chugai Pharmaceutical Co Ltd |
método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca)
|
US11066483B2
(en)
|
2010-11-30 |
2021-07-20 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
JP6157045B2
(ja)
*
|
2010-12-06 |
2017-07-05 |
公益財団法人がん研究会 |
Cd20認識モノクローナル抗体、ハイブリドーマ、cd20の検出方法および判定方法
|
BR112013014522A2
(pt)
|
2010-12-16 |
2017-09-26 |
Roche Glycart Ag |
anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
|
WO2012096924A1
(en)
*
|
2011-01-10 |
2012-07-19 |
Glaxo Group Limited |
Novel uses
|
BR112013021725A2
(pt)
|
2011-02-28 |
2016-11-01 |
Genentech Inc |
marcadores biológicos e métodos para prever resposta aos antagonistas de células b
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
NZ724296A
(en)
|
2011-05-13 |
2020-05-29 |
Ganymed Pharmaceuticals Ag |
Antibodies for treatment of cancer expressing claudin 6
|
SI2714733T1
(sl)
|
2011-05-21 |
2019-06-28 |
Macrogenics, Inc. |
CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
WO2013004841A1
(en)
|
2011-07-06 |
2013-01-10 |
Genmab A/S |
Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
CN103827143A
(zh)
|
2011-07-06 |
2014-05-28 |
莫弗系统股份公司 |
抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
|
CN102875678B
(zh)
*
|
2011-07-13 |
2014-08-06 |
无锡天演生物技术有限公司 |
全人源抗人cd20单抗分子及其应用
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
JP5813880B2
(ja)
*
|
2011-09-19 |
2015-11-17 |
カイマブ・リミテッド |
ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
|
CN110511939A
(zh)
|
2011-10-03 |
2019-11-29 |
现代泰克斯公司 |
修饰的核苷、核苷酸和核酸及其用途
|
AU2012328819B2
(en)
|
2011-10-26 |
2017-08-03 |
Elanco Tiergesundheit Ag |
Monoclonal antibodies and methods of use
|
LT2771364T
(lt)
|
2011-10-27 |
2019-09-10 |
Genmab A/S |
Heterodimerinių baltymų gamyba
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
TR201815709T4
(tr)
|
2011-12-22 |
2018-11-21 |
Hoffmann La Roche |
İyon değişim membranı kromatografisi.
|
MX2014009043A
(es)
|
2012-01-31 |
2014-10-14 |
Genentech Inc |
Anticuerpos anti-ige y sus metodos de uso.
|
CN102585000B
(zh)
*
|
2012-02-22 |
2013-05-29 |
尉军 |
一种肿瘤标志物cd25自身抗体及应用
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
EP2833923A4
(en)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
EP2662386B1
(en)
|
2012-05-07 |
2019-03-06 |
Astellas Pharma Inc. |
Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
WO2013169971A1
(en)
|
2012-05-10 |
2013-11-14 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
BR112014028600B1
(pt)
|
2012-05-18 |
2022-11-22 |
Genentech, Inc |
Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
|
WO2013174403A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
DK3254695T3
(da)
|
2012-05-23 |
2020-11-30 |
Astellas Pharma Inc |
Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
|
WO2013174404A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
EP3725810B1
(en)
|
2012-05-23 |
2022-07-06 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
WO2014006217A1
(en)
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
ES2758979T3
(es)
*
|
2012-07-06 |
2020-05-07 |
Genmab Bv |
Proteína dimérica con mutaciones triples
|
CN103588882B
(zh)
*
|
2012-08-13 |
2015-10-28 |
中国抗体制药有限公司 |
针对人cd22抗体的抗独特型抗体及其应用
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
CA2883168A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US8643360B1
(en)
*
|
2012-09-02 |
2014-02-04 |
George S. Cargill, III |
In-water voltage gradient detector
|
KR20200110711A
(ko)
|
2012-09-07 |
2020-09-24 |
제넨테크, 인크. |
Ii형 항-cd20 항체와 선택적 bcl-2 억제제와의 병용 치료요법
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
US9492563B2
(en)
|
2012-10-30 |
2016-11-15 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
WO2014075697A1
(en)
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents for treatment of claudin expressing cancer diseases
|
BR122020024124B1
(pt)
|
2012-11-13 |
2024-01-30 |
Biontech Ag |
Agentes para tratamento de doenças cancerosas expressando claudina
|
KR102381936B1
(ko)
*
|
2012-11-13 |
2022-04-01 |
비온테크 에스이 |
클라우딘 발현 암 질환의 치료제
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
CN103173412B
(zh)
*
|
2012-12-07 |
2015-04-22 |
天津三箭生物技术有限公司 |
小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
|
KR20200134340A
(ko)
|
2013-01-10 |
2020-12-01 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
CN103145847B
(zh)
*
|
2013-02-05 |
2014-05-21 |
浙江大学 |
一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
|
EP4177273A1
(en)
|
2013-02-20 |
2023-05-10 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
WO2014127785A1
(en)
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
SG11201507475UA
(en)
|
2013-03-13 |
2015-10-29 |
Genentech Inc |
Antibody formulations
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
FR3003171B1
(fr)
*
|
2013-03-15 |
2015-04-10 |
Lab Francais Du Fractionnement |
Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
|
SI2976360T1
(sl)
|
2013-03-18 |
2020-04-30 |
Astellas Pharma Inc. |
Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
|
WO2014146672A1
(en)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
RU2015147696A
(ru)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
Способы лечения злокачественной опухоли
|
CN109395064A
(zh)
|
2013-04-19 |
2019-03-01 |
赛腾制药 |
降低的血管渗漏综合征的细胞因子衍生治疗
|
CN103254317B
(zh)
*
|
2013-05-08 |
2014-08-13 |
浙江大学 |
一种抗cd20单克隆抗体-海兔毒素偶联物及其制备方法和应用
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
AU2014286116A1
(en)
*
|
2013-07-05 |
2016-02-04 |
Genmab A/S |
Humanized or chimeric CD3 antibodies
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
EP3738611A1
(en)
|
2013-07-31 |
2020-11-18 |
BioNTech AG |
Diagnosis and therapy of cancer involving cancer stem cells
|
KR102564207B1
(ko)
|
2013-08-08 |
2023-08-10 |
싸이튠 파마 |
Il―15 및 il―15r 알파 스시 도메인 기반 모듈로카인
|
KR102457731B1
(ko)
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
CN103467605B
(zh)
*
|
2013-09-05 |
2015-02-04 |
武汉友芝友生物制药有限公司 |
一种cd3抗原及其制备方法和用途
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
WO2015069770A1
(en)
|
2013-11-05 |
2015-05-14 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
EP3066127A1
(en)
|
2013-11-06 |
2016-09-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
CA2926893C
(en)
*
|
2013-11-07 |
2022-04-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti cd20 antibody with a btk inhibitor
|
CA2963178C
(en)
|
2013-11-12 |
2023-01-24 |
Ogd2 Pharma |
Human igg1 derived antibody with pro-apoptotic activity
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP2910645A1
(en)
|
2014-02-25 |
2015-08-26 |
STRATIFYER Molecular Pathology GmbH |
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
CN103880957B
(zh)
*
|
2014-03-27 |
2016-01-20 |
安徽大学 |
抗cd20抗原的抗体l1h1及其应用
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
CN103880958B
(zh)
*
|
2014-03-27 |
2016-01-20 |
安徽大学 |
抗cd20抗原的抗体l4h6及其应用
|
CA2943943C
(en)
|
2014-04-07 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
EP3909602A1
(en)
|
2014-04-25 |
2021-11-17 |
University of Florida Research Foundation, Inc. |
Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
|
KR20230164192A
(ko)
|
2014-05-06 |
2023-12-01 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
EP4116329A1
(en)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
TWI717319B
(zh)
|
2014-05-27 |
2021-02-01 |
中央研究院 |
得自類桿菌屬之岩藻糖苷酶及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
ES2796903T3
(es)
|
2014-09-23 |
2020-11-30 |
Hoffmann La Roche |
Procedimiento de uso de inmunoconjugados anti-CD79b
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016057898A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
CA2967820A1
(en)
|
2014-11-17 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
EP3227335A1
(en)
|
2014-12-04 |
2017-10-11 |
Bristol-Myers Squibb Company |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
DK3233907T3
(da)
|
2014-12-19 |
2021-06-07 |
Genmab As |
Bispecifikke heterodimeriske proteiner hos gnavere
|
CN107660214B
(zh)
*
|
2015-01-08 |
2022-02-08 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
EP3250588A1
(en)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Cryptic polypeptides and uses thereof
|
US10787520B2
(en)
*
|
2015-03-04 |
2020-09-29 |
Igm Biosciences, Inc. |
Multimeric bispecific binding molecules specific for CD20 and CD3
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
WO2016165765A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
|
CN107529739B
(zh)
*
|
2015-04-30 |
2021-01-08 |
株式会社特殊免疫研究所 |
表达人特定分子和人Fcγ受体家族的转基因非人动物
|
EP3736287A1
(en)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
WO2016183104A1
(en)
|
2015-05-11 |
2016-11-17 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
CA3025145A1
(en)
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
EA201792623A1
(ru)
|
2015-06-03 |
2018-04-30 |
Бостон Биомедикал, Инк. |
Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
RS62986B1
(sr)
|
2015-06-24 |
2022-03-31 |
Hoffmann La Roche |
Antitela na transferinski receptor sa prilagođenim afinitetom
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
ES2886657T3
(es)
|
2015-06-29 |
2021-12-20 |
Bristol Myers Squibb Co |
Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
|
JP2018520153A
(ja)
|
2015-06-29 |
2018-07-26 |
ジェネンテック, インコーポレイテッド |
臓器移植における使用のためのii型抗cd20抗体
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
WO2017009842A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
WO2017023753A1
(en)
|
2015-07-31 |
2017-02-09 |
University Of Florida Research Foundation, Inc. |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
US11098079B2
(en)
|
2015-08-13 |
2021-08-24 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
TWI747843B
(zh)
|
2015-10-02 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
IL299203A
(en)
*
|
2015-10-13 |
2023-02-01 |
Eureka Therapeutics Inc ׂ A Delaware Corp |
Antibody factors specific for human differentiation group 19 and their uses
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CN105348388B
(zh)
*
|
2015-12-11 |
2018-10-19 |
安徽大学 |
抗cd20抗原的抗体l3h3及其应用
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
AU2016380988B2
(en)
|
2015-12-30 |
2022-07-21 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
WO2017149018A1
(en)
|
2016-03-02 |
2017-09-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
US11072666B2
(en)
|
2016-03-14 |
2021-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
FI3429618T3
(fi)
|
2016-03-16 |
2024-03-15 |
Amal Therapeutics Sa |
Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön
|
WO2017182608A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
US11052148B2
(en)
|
2016-05-30 |
2021-07-06 |
Geo Vax, Inc. |
Compositions and methods for generating an immune response to hepatitis B virus
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
AU2017283470B2
(en)
|
2016-06-14 |
2024-03-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-C5 antibodies and uses thereof
|
JP2019525138A
(ja)
*
|
2016-06-16 |
2019-09-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Cdcを誘発する抗体を決定するためのアッセイ法および方法
|
SG11201811600PA
(en)
|
2016-06-30 |
2019-01-30 |
Oncorus Inc |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
CN106267406B
(zh)
*
|
2016-07-01 |
2019-02-01 |
翁炳焕 |
艾滋病血液净化器
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
US11414495B2
(en)
*
|
2016-09-01 |
2022-08-16 |
Tiga Tx, Inc. |
CD20 antibodies
|
KR20190057345A
(ko)
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
WO2018054484A1
(en)
|
2016-09-23 |
2018-03-29 |
Biontech Ag |
Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
|
JP7277363B2
(ja)
|
2016-11-01 |
2023-05-18 |
ジェンマブ ビー.ブイ. |
ポリペプチド変異体およびその使用
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
KR20190090822A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
AU2017369994A1
(en)
|
2016-12-01 |
2019-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
WO2018100096A1
(en)
|
2016-12-01 |
2018-06-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
|
US10610104B2
(en)
|
2016-12-07 |
2020-04-07 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
CA3039430A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
CA3039446A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
JP7139332B2
(ja)
|
2016-12-23 |
2022-09-20 |
ノバルティス アーゲー |
第xi因子抗体および使用方法
|
AU2018219862B2
(en)
|
2017-02-07 |
2020-09-17 |
Nant Holding IP, LLC |
Maximizing T-cell memory and compositions and methods therefor
|
CN108395482B
(zh)
*
|
2017-02-08 |
2021-02-05 |
西比曼生物科技(香港)有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
SG11201906961UA
(en)
|
2017-02-10 |
2019-08-27 |
Genmab Bv |
Polypeptide variants and uses thereof
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
WO2018178396A1
(en)
|
2017-03-31 |
2018-10-04 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
WO2018226336A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
|
CN107446046A
(zh)
*
|
2017-07-05 |
2017-12-08 |
无锡傲锐东源生物科技有限公司 |
抗cd20蛋白单克隆抗体及其用途
|
EP3658584A1
(en)
|
2017-07-26 |
2020-06-03 |
H. Hoffnabb-La Roche Ag |
Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
|
CN111511762A
(zh)
|
2017-08-21 |
2020-08-07 |
天演药业公司 |
抗cd137分子及其用途
|
WO2019048040A1
(en)
|
2017-09-06 |
2019-03-14 |
Ganymed Pharmaceuticals Gmbh |
ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
|
WO2019077123A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
CN111212660A
(zh)
|
2017-12-14 |
2020-05-29 |
豪夫迈·罗氏有限公司 |
Cea cd3双特异性抗体和pd-1轴结合拮抗剂在治疗癌症的剂量方案中的用途
|
WO2019126691A1
(en)
|
2017-12-21 |
2019-06-27 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
US20210030703A1
(en)
|
2018-03-12 |
2021-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
TW202003561A
(zh)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
EP3765489A1
(en)
|
2018-03-13 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
KR20210008380A
(ko)
|
2018-05-03 |
2021-01-21 |
젠맵 비. 브이 |
항체 변이체 조합물 및 그의 용도
|
WO2019232319A1
(en)
|
2018-05-31 |
2019-12-05 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting cd73
|
EP3807410A1
(en)
|
2018-06-15 |
2021-04-21 |
MiNA Therapeutics Limited |
Combination therapies comprising c/ebp alpha sarna
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
SG11202012713RA
(en)
|
2018-06-22 |
2021-01-28 |
Genmab As |
Method for producing a controlled mixture of two or more different antibodies
|
JP2021528439A
(ja)
|
2018-06-22 |
2021-10-21 |
ゲンマブ ホールディング ビー.ブイ. |
抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法
|
JP7352582B2
(ja)
*
|
2018-07-09 |
2023-09-28 |
武田薬品工業株式会社 |
Sumo活性化酵素阻害剤及び抗cd20抗体の投与
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
MX2021002190A
(es)
|
2018-08-31 |
2021-05-14 |
Regeneron Pharma |
Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
WO2020061048A1
(en)
|
2018-09-17 |
2020-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
WO2020070053A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
KR20210116429A
(ko)
|
2018-10-04 |
2021-09-27 |
젠맵 홀딩 비.브이. |
이중특이적 항-cd37 항체를 포함하는 제약 조성물
|
KR102262012B1
(ko)
|
2018-10-15 |
2021-06-09 |
연세대학교 산학협력단 |
생산성이 향상된 항체 및 이의 제조방법
|
CA3100232A1
(en)
*
|
2018-10-26 |
2020-04-30 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
WO2020106750A1
(en)
|
2018-11-19 |
2020-05-28 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
US11279698B2
(en)
|
2018-11-20 |
2022-03-22 |
Cornell University |
Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
|
WO2020109355A1
(en)
|
2018-11-28 |
2020-06-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kit for assaying lytic potential of immune effector cells
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
US20220018835A1
(en)
|
2018-12-07 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
AU2019396360A1
(en)
|
2018-12-11 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
SG11202107606VA
(en)
|
2019-01-15 |
2021-08-30 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
TW202102266A
(zh)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
用於穩定含有蛋白質之配方之組合物及方法
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
US20220160692A1
(en)
|
2019-04-09 |
2022-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
WO2020212484A1
(en)
|
2019-04-17 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
CN114206340A
(zh)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えad35ベクター及び関連遺伝子治療改善
|
CN110551221B
(zh)
|
2019-07-02 |
2021-03-05 |
广州爱思迈生物医药科技有限公司 |
一种双特异性抗体及其制备方法与应用
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
WO2021041678A1
(en)
*
|
2019-08-30 |
2021-03-04 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
|
MX2022003030A
(es)
|
2019-09-11 |
2022-04-07 |
Novartis Ag |
Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab.
|
KR20220062025A
(ko)
|
2019-09-11 |
2022-05-13 |
노파르티스 아게 |
요법 교체에 의한 rms의 치료
|
JP2022547577A
(ja)
|
2019-09-12 |
2022-11-14 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
WO2021058091A1
(en)
|
2019-09-24 |
2021-04-01 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment involving therapeutic antibody and interleukin-2 (il2)
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
PE20221039A1
(es)
|
2019-10-18 |
2022-06-17 |
Genentech Inc |
METODOS PARA USAR INMUNOCONJUGADOS ANTI-CD79b PARA TRATAR LINFOMA DIFUSO DE LINFOCITOS B GRANDES
|
JP2023500701A
(ja)
|
2019-11-06 |
2023-01-10 |
ジェンマブ ビー.ブイ. |
抗体変種の組み合わせおよびその使用
|
EP4061809A1
(en)
|
2019-11-22 |
2022-09-28 |
Theravance Biopharma R&D IP, LLC |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
CN111100204B
(zh)
*
|
2019-11-26 |
2022-03-11 |
山东立菲生物产业有限公司 |
靶向cd20的抗体、其制备方法和应用
|
CN115666704A
(zh)
|
2019-12-13 |
2023-01-31 |
比奥拉治疗股份有限公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
EP4107529A1
(en)
|
2020-02-21 |
2022-12-28 |
Genmab B.V. |
Methods for the quantification of glycoproteins
|
US11673879B2
(en)
|
2020-03-31 |
2023-06-13 |
Theravance Biopharma R&D Ip, Llc |
Substituted pyrimidines and methods of use
|
MX2022012600A
(es)
|
2020-04-09 |
2023-02-15 |
Novartis Ag |
Ofatumumab para el tratamiento de ms mientras se mantiene la igg en el suero.
|
EP4139289A1
(en)
|
2020-04-21 |
2023-03-01 |
University of Rochester |
Inhibitors of human epididymus protein 4
|
WO2021216920A1
(en)
|
2020-04-22 |
2021-10-28 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods for using anti-cd79b immunoconjugates
|
IL297986A
(en)
|
2020-05-08 |
2023-01-01 |
Genmab As |
Bispecific antibodies against cd3 and cd20
|
CN115768885A
(zh)
|
2020-06-03 |
2023-03-07 |
Mv生物治疗股份有限公司 |
Atp水解酶和免疫检查点调节剂的组合及其应用
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
JP2023532768A
(ja)
|
2020-07-07 |
2023-07-31 |
バイオエヌテック エスエー |
Hpv陽性癌の治療用rna
|
CA3184940A1
(en)
|
2020-07-07 |
2022-01-13 |
Jennifer Donglan WU |
Mic antibodies and binding agents and methods of using the same
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
CN112062855A
(zh)
*
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
WO2022043415A1
(en)
|
2020-08-27 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for detecting the presence of pemphigus-specific autoantibodies in a sample
|
EP4210746A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー/エス |
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
AU2021341509A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
|
US20230355753A1
(en)
|
2020-09-10 |
2023-11-09 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
EP4210745A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230399403A1
(en)
|
2020-11-11 |
2023-12-14 |
BioNTech SE |
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
MX2023007846A
(es)
|
2021-01-06 |
2023-07-07 |
F Hoffmann La Roche Ag |
Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
|
TW202300521A
(zh)
|
2021-03-15 |
2023-01-01 |
美商建南德克公司 |
治療狼瘡性腎炎的組成物及方法
|
CA3212978A1
(en)
|
2021-03-24 |
2022-09-29 |
James N. KOCHENDERFER |
Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
CA3214598A1
(en)
|
2021-03-26 |
2022-09-29 |
BioNTech SE |
Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
IL307464A
(en)
|
2021-04-14 |
2023-12-01 |
Novartis Ag |
OFATUMUMAB for the treatment of multiple sclerosis in Asian patients
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
WO2022229644A1
(en)
|
2021-04-28 |
2022-11-03 |
Mina Therapeutics Limited |
Combination therapies comprising c/ebp alpha sarna
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
WO2022236047A1
(en)
|
2021-05-07 |
2022-11-10 |
Viela Bio, Inc. |
Use of an anti-cd19 antibody to treat myasthenia gravis
|
EP4337266A1
(en)
|
2021-05-12 |
2024-03-20 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
WO2022253756A1
(en)
|
2021-06-01 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of b cell depleting agents for the treatment of rheumatic heart disease
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
CA3220318A1
(en)
|
2021-06-17 |
2022-12-22 |
Glaxosmithkline Intellectual Property Limited |
Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc)
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
IL309831A
(en)
|
2021-07-13 |
2024-02-01 |
BioNTech SE |
Multispecific binding agents against CD40 and CD137 in combined cancer therapy
|
US20230099756A1
(en)
|
2021-08-07 |
2023-03-30 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
KR20240046200A
(ko)
|
2021-08-16 |
2024-04-08 |
노파르티스 아게 |
소아 ms 치료를 위한 오파투무맙
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
WO2023144290A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230303693A1
(en)
|
2022-01-28 |
2023-09-28 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
WO2023217987A1
(en)
|
2022-05-12 |
2023-11-16 |
BioNTech SE |
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
|
CN116162153A
(zh)
*
|
2022-09-01 |
2023-05-26 |
复旦大学附属中山医院 |
一种乙肝病毒表面抗原的单克隆抗体及其应用
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|